<DOC>
	<DOCNO>NCT00807651</DOCNO>
	<brief_summary>This phase II trial individual diagnose type 1 diabetes within previous 6 month . The study evaluate whether stem cell transplantation safe chemotherapy immunotherapy use combination immune reset effect may halt immune attack pancreas islet thus preserve body 's insulin production .</brief_summary>
	<brief_title>Autologous Hematopoietic Stem Cell Transplantation Early Onset Type 1 Diabetes</brief_title>
	<detailed_description>Type 1 diabetes autoimmune disease immune system mistakenly attack insulin-producing beta cell pancreas . Generally , time someone diagnose type 1 diabetes , person 's beta cell destroy . It 's important preserve remain precious beta cell stop diabetes progression . The exact mechanism action Autologous Hematopoietic Stem Cell Transplantation ( AHST ) autoimmune disorder fully understood . Preliminary data support post-AHST immune reset included increase thymus-derived naive T cell , decrease central-memory T cell , increase output recent thymic emigrant , recovery diverse distinct T-cell receptor repertoire follow AHST . In patient type 1 diabetes , decrease titer anti-GAD antibody may bring improvement beta-cell function intensive immunosuppression . Furthermore , may exit possibility regeneration beta cell survive beta cell pancreatic bone marrow stem cell . Patients recently diagnose ( less 6 month ) type 1 diabetes mellitus prove positive antibody glutamic acid decarboxylase include study . Hematopoietic stem cell mobilize cyclophosphamide ( 2.0 g/m2 ) granulocyte colonystimulating factor ( 10 Î¼g/kg per day ) collect peripheral blood leukapheresis cryopreserved . The cell inject intravenously condition cyclophosphamide ( 200 mg/kg ) rabbit antithymocyte globulin ( 4.5 mg/kg ) . This procedure perform isolated room Bone Marrow Transplantation Unit Shanghai Ruijin Hospital affiliate Shanghai Jiao-Tong University School Medicine . Patients discharge hospital 1 month transplantation continue follow-ups 3 year . Patients fit inclusion criterion agree perform transplantation control group follow parallel transplant patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes mellitus diagnose clinical/metabolic parameter positive antiGAD antibody Less 6 month diagnosis Previous diabetic ketoacidosis Pregnancy Severe psychiatric disorder Severe organic impairment ( renal , hepatic , cardiac , pulmonary ) Active infectious disease Previous present neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>